Dr. Ray Rogers Glendrange, MD

Dr. Glendrange practices at Riverside Eye Specialists Medical Group Inc. in Riverside, California.

Dr. Glendrange's NPI, 1164484507, was assigned on April 3, 2006. Dr. Glendrange graduated from Loma Linda University School Of Medicine in 1986. Dr. Glendrange's California license number on file is G61038.

Dr. Glendrange's primary practice is Riverside Eye Specialists Medical Group Inc., at 4605 Brockton Ave, Riverside, CA 92506 in Riverside County. The practice phone is (951) 686-4911.

Dr. Glendrange's primary practice is Riverside Eye Specialists Medical Group Inc. in Riverside, California. Dmand AI also links Dr. Glendrange to 1 group practice or clinic and 1 medical group, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Glendrange practices. Vendor and product names are available with a free account.

Ophthalmology is Dr. Glendrange's primary specialty in the NPI Registry, under taxonomy code 207W00000X. Dr. Glendrange is board certified in ophthalmology by the American Board of Ophthalmology. Dr. Glendrange has a license on file in California.

Dmand AI lists age-related macular degeneration, cataract, cataract surgery with lens implant, cold sores or genital herpes, conjunctivitis, dry eye, eye infection or inflammation and eyelid inflammation among the conditions Dr. Glendrange treats.

CMS data shows 3,118 Medicare services from Dr. Glendrange across 16 procedure codes in 2024, for 879 Medicare patients. Medicare paid $275,144 for them.

CMS counts 879 Medicare patients who saw Dr. Glendrange in 2024. The largest group is 75 to 84, with 357 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 19% are also on Medicaid. Their average risk score is 1.51, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Glendrange's median patient age at 72, with 58% women.

In 2024, Dr. Glendrange wrote 4,144 Medicare Part D claims for 891 patients. 56% of them were for generic drugs. CMS names the drug for 4,048 of them, across 31 drugs with 11 or more claims each, at $434,968 in total drug cost. In 2023, CMS named 3,776 claims across 29 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 92 out of 100 for Dr. Glendrange for performance year 2024, reported individually. Dr. Glendrange accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS counts 225 procedures of cataract surgery by Dr. Glendrange, more than 85% of the clinicians it reports for that procedure.

CMS Open Payments shows 102 general payments to Dr. Glendrange from 20 drug and device companies from 2016 to 2025. Food and beverage make up the largest share, 96% of the total. Alcon Laboratories Inc paid the most, $1,139.

Dr. Glendrange graduated from Loma Linda University School Of Medicine in 1986.

Dr. Glendrange is in network with 16 carriers, including Blue Cross Blue Shield of Michigan, United Healthcare and Elevance. PPO plans come from the most carriers, 10. Check the plan with the practice before a visit.